从资金流向上来看，当日生物制品板块主力资金净流入1.91亿元，游资资金净流出2.73亿元，散户资金净 流入8203.94万元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002773 康弘药业 | | 1.18 Z | 18.31% | -3021.77万 | -4.70% | -8748.13万 | -13.61% | | 000661 | 长春高新 | 7444.34万 | 9.43% | -4755.38万 | -6.02% | -2688.95万 | -3.40% | | 688331 荣昌生物 | | 6982.31万 | 10.14% | -2366.87万 | -3.44% | -4615.43万 | -6.71% | | 300122 智飞生物 | | 3724.35万 | 9.83% | 85.58万 | 0.23% | -3809.93万 | -10.05% ...

每经AI快讯，西藏药业1月5日晚间发布公告称，2026年1月5日，公司通过上海证券交易所交易系统以 集中竞价交易方式首次回购公司股份3800股，占公司总股本的比例为0.0012%，购买的最高价为42.99 元/股，最低价为42.95元/股，已支付的总金额为人民币约16万元。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 （记者 王晓波） ...

证券代码：600211 证券简称：西藏药业 公告编号：2026-001 西藏诺迪康药业股份有限公司 关于首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/12/19，由董事会提议 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2025 18 12 | 12 | 月 | 日~2026 | 年 | 月 | 17 | 日 | | 预计回购金额 | 17,000万元~20,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 3,800股 | | | | | | | | | 累计已回购股数占总股本比 ...

格隆汇1月5日丨西藏药业(600211.SH)公布，2026年1月5日，公司通过上海证券交易所交易系统以集中 竞价交易方式首次回购公司股份3800股，占公司总股本的比例为0.0012%，购买的最高价为42.99元/ 股，最低价为42.95元/股，已支付的总金额为人民币163,278.00元（不含印花税、交易佣金等交易费 用）。 ...

格隆汇1月5日丨西藏药业(600211.SH)公布，2026年1月5日，公司通过上海证券交易所交易系统以集中 竞价交易方式首次回购公司股份3800股，占公司总股本的比例为0.0012%，购买的最高价为42.99元/ 股，最低价为42.95元/股，已支付的总金额为人民币163,278.00元（不含印花税、交易佣金等交易费 用）。 ...

Core Viewpoint - The biopharmaceutical sector experienced a slight decline of 0.34% on December 30, with Wanze Co., Ltd. leading the losses. The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1]. Group 1: Market Performance - The biopharmaceutical sector's performance showed mixed results, with individual stocks experiencing varying degrees of gains and losses. Notably, Aidi Pharmaceutical saw a rise of 4.10% to close at 15.98, while Wanze Co., Ltd. fell by 6.76% to 21.94 [1][2]. - The trading volume for Aidi Pharmaceutical was 93,900 shares, with a transaction value of 150 million yuan, indicating strong investor interest [1]. Group 2: Capital Flow - The biopharmaceutical sector faced a net outflow of 330 million yuan from institutional investors, while retail investors contributed a net inflow of 349 million yuan, suggesting a shift in investor sentiment [2]. - The data indicates that while institutional investors withdrew funds, retail investors were more active in purchasing shares within the sector [2][3]. Group 3: Individual Stock Analysis - Ganne Pharmaceutical experienced a net outflow of 34.73 million yuan from institutional investors, while retail investors showed a net inflow of 129.36 million yuan, reflecting a divergence in investment strategies [3]. - Other notable stocks included Huashan Biological, which had a net inflow of 430.99 million yuan from institutional investors, indicating positive sentiment towards its performance [3].

证券代码：600211 证券简称：西藏药业 公告编号：2025-046 西藏诺迪康药业股份有限公司 关于以集中竞价方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 17,000 万元（含），不高于人民币 20,000 万元（含）。 3、公司本次回购股份拟在未来适宜时机用于股权激励或员工持股计划，若公司未能在 法律法规规定的期限内实施上述用途，则存在已回购股份全部或部分无法授出从而将被予 以注销的风险。 4、如遇监管部门颁布新的回购相关规范性文件，可能导致本次回购实施过程中需要根 ● 回购股份资金来源：公司自有资金 ● 回购股份用途：用于实施股权激励或员工持股计划。若公司未能在股份回购实施结果暨 股份变动公告日后三年内转让完毕，未转让股份将依法履行相关程序予以注销。 ● 回购股份价格：不超过人民币 55 元/股（含）。该价格不高于公司董事会通过回购股份 决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：集中竞价交易方式 ● 回购股份 ...

Core Viewpoint - The company plans to repurchase shares through a centralized bidding method, with an amount between 170 million and 200 million yuan, at a price not exceeding 55 yuan per share [1] Group 1: Share Repurchase Details - The repurchase is expected to involve 3,090,909 to 3,636,364 shares, representing 0.96% to 1.13% of the total share capital [1] - The funding for the repurchase will come from the company's own funds [1] - The repurchased shares will be used for equity incentives or employee stock ownership plans, and any shares not transferred within three years will be canceled [1] Group 2: Timeline and Impact - The repurchase will take place within 12 months from the board's approval [1] - The company's directors, supervisors, and controlling shareholders have no plans to reduce their holdings in the next three to six months [1] - The company believes that the repurchase will not have a significant impact on its operations [1]

Group 1 - The company announced a share buyback plan to be approved at the fourth temporary meeting of the eighth board of directors on December 18, 2025 [1] - The top ten unrestricted shareholders hold approximately 202 million shares, accounting for 62.65% of the total shares [1] - The largest shareholder is Xizang Kangzhe Enterprise Management Co., Ltd., holding about 104 million shares, which is 32.28% of the total [1] Group 2 - For the first half of 2025, the company's revenue composition shows that pharmaceutical commerce accounts for 97.37%, while pharmaceutical manufacturing accounts for 68.9% [2] - Other business segments contribute only 0.2%, with inter-segment eliminations at -66.47% [2] Group 3 - The company's market capitalization is currently 13.6 billion yuan [3]

西藏诺迪康药业股份有限公司 证券代码：600211 证券简称：西藏药业 公告编号：2025-045 | 序号 | 股东名称 | 持股数量（股） | 占公司总股本比例（%） | | --- | --- | --- | --- | | 1 | 西藏康哲企业管理有限公司 | 104,043,393 | 32.28 | | 2 | 西藏华西药业集团有限公司 | 56,148,300 | 17.42 | | 3 | 北京新凤凰城房地产开发有限公司 | 10,283,000 | 3.19 | | 4 | 深圳市康哲药业有限公司 | 10,021,297 | 3.11 | | 5 | 天津康哲医药科技发展有限公司 | 6,339,438 | 1.97 | | 6 | 西藏科技创新投资有限责任公司 | 6,199,000 | 1.92 | | 7 | 香港中央结算有限公司 | 3,056,600 | 0.95 | | 8 | 国金证券（香港）有限公司－客户资金（交易所） | 2,408,925 | 0.75 | | 9 | 上海银行股份有限公司－银华中证创新药产业 交易型开放式指数证券投资基金 | 1,958,504 | 0 ...